Suzhou Ribo Life Science and Ribocure Pharmaceuticals (Ribo) announced a $2 billion collaboration with Boehringer Ingelheim to develop novel treatments for nonalcoholic or metabolic dysfunction-associated steatohepatitis (NASH/MASH).
Source: Drug Industry Daily